



# The “Next Day” Effects of Cannabis Use: A Systematic Review

Danielle McCartney,<sup>1–3,\*</sup> Anastasia Suraev,<sup>1–3</sup> and Iain S. McGregor<sup>1–3</sup>

## Abstract

**Background:**  $\Delta^9$ -Tetrahydrocannabinol (THC), the main intoxicating component of cannabis, can cause cognitive and psychomotor impairment. Whether this impairment is still present many hours or even days after THC use requires clarification. Possible “next day” effects are of major significance in safety-sensitive workplaces. We therefore conducted a systematic review of studies investigating the “next day” effects of THC.

**Methods:** Studies that measured performance on safety-sensitive tasks (e.g., driving, flying) and/or neuropsychological tests >8 h after THC (or cannabis) use using interventional designs were identified by searching two online databases from inception until March 28, 2022. Risk of bias (RoB) was evaluated using the relevant Cochrane tools. Results were described in terms of whether THC had a significant effect on performance relative to the primary comparator (i.e., placebo or baseline, as appropriate).

**Results:** Twenty studies ( $n=458$ ) involving 345 performance tests were reviewed. Most studies administered a single dose of THC (median [interquartile range]: 16 [11–26] mg) and assessed performance between >12 and 24 h post-treatment.  $N=209/345$  tests conducted across 16 published studies showed no “next day” effects of THC. Nine of these 16 studies used randomized, double-blind, placebo-controlled designs. Half ( $N=8$ ) had “some” RoB, and half ( $N=8$ ) had a “high” RoB. Notably,  $N=88$  of these 209 tests failed to demonstrate “acute” (i.e., <8 h post-treatment) THC-induced impairment.  $N=12/345$  tests conducted across five published studies indicated negative (i.e., impairing) “next day” effects of THC. None of these five studies used randomized, double-blind, placebo-controlled designs and all were published >18 years ago (four, >30 years ago). Three had “some” RoB, and two had a “high” RoB. A further  $N=121/345$  tests indicated “unclear” “next day” effects of THC with insufficient information provided to assess outcomes. The remaining  $N=3/345$  tests indicated positive (i.e., enhancing) “next day” effects of THC.

**Conclusions:** Some lower quality studies have reported “next day” effects of THC on cognitive function and safety-sensitive tasks. However, most studies, including some of higher quality, have found no such effect. Overall, it appears that there is limited scientific evidence to support the assertion that cannabis use impairs “next day” performance. Further studies involving improved methodologies are required to better address this issue.

**Keywords:** cannabis; THC; cannabinoids; impairment; cognitive function; driving

## Introduction

Two hundred million people use cannabis each year.<sup>1</sup> This includes those using cannabis for its euphorogenic effects (i.e., so-called “recreational” users) and, increasingly, those using it to treat medical conditions such as chronic pain, insomnia, and anxiety.<sup>2</sup>

The potential harms associated with cannabis use have been debated over many decades. One ongoing concern is that the major cannabis constituent,  $\Delta^9$ -tetrahydrocannabinol (THC), can induce intoxication and impair cognitive and psychomotor performance (e.g., reaction time, working memory, divided attention),<sup>3</sup>

<sup>1</sup>Lambert Initiative for Cannabinoid Therapeutics and <sup>2</sup>Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.

<sup>3</sup>School of Psychology, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia.

\*Address correspondence to: Danielle McCartney, PhD, Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Camperdown, NSW 2050, Australia, E-mail: danielle.mccartney@sydney.edu.au

© Danielle McCartney et al., 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License [CC-BY-NC] (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

increasing the risk of error, accident, and injury when operating a motor vehicle or engaging in other safety-sensitive tasks.<sup>4–6</sup> Indeed, epidemiological studies suggest that “THC-positive” drivers are between ~1.1 and 1.4 times more likely to become crash-involved than other drivers.<sup>7</sup>

The duration of THC-induced impairment, or length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue. A recent meta-regression analysis<sup>3</sup> concluded that there was a “window of impairment” extending from ~3 to 10 h after THC use, with the exact duration dependent on the following: (1) *dose*: higher THC doses produced longer lasting impairment; (2) *route of administration*: oral THC produced longer lasting impairment than inhaled THC (e.g., smoked, vaporized), owing to the fact that gastrointestinal absorption is slower than pulmonary absorption<sup>8,9</sup>; and (3) *regularity of cannabis use*: occasional cannabis users became more impaired than regular cannabis users (who appear to be more tolerant to the impairing effects of THC<sup>10</sup>). This review did not, however, include performance tests conducted >12 h after THC use.

Some government agencies and experts in occupational safety caution that THC-induced impairment may persist for >24 h and recommend that individuals avoid performing safety-sensitive tasks for at least this long after cannabis use.<sup>11,12</sup> This can impact upon those who are reliant on driving for their work and/or family life, and upon individuals employed in safety-sensitive positions (e.g., transit and construction workers, defense personnel), who may use cannabis “off-duty” (e.g., in the evening, on the weekend) to treat conditions such as insomnia and chronic pain. However, such advice does not appear to have been informed by a comprehensive review of the scientific evidence.

We therefore conducted a systematic review to better understand the “next day” (i.e., >8 h) effects of THC use on cognitive function and safety-sensitive tasks.

## Methods

The methods of this review were developed in accordance with the *Cochrane Handbook for Systematic Reviews of Interventions* (Version 6.2, 2021).<sup>13</sup>

### Literature search

Relevant studies were identified by searching the online databases Scopus and Web of Science (Thomas Reuters) from inception until March 28, 2022, using the Boolean expression in Supplementary File S1. Two

investigators (D.M. and A.S.) independently screened all titles and abstracts against the following inclusion criteria: (1) English language; (2) full-length article; (3) original research; (4) interventional design; and (5) THC administration. Suitable records were then screened for eligibility by full text (see “Eligibility criteria” section). The final decision to include (or discard) a study was made between these two investigators; discrepancies were resolved in discussion with a third investigator (I.S.M.). One investigator (D.M.) also hand-searched the reference lists of the included publications and two previous reviews<sup>3,14</sup> to ensure all relevant articles were captured.

### Eligibility criteria

Studies that measured performance on “safety-sensitive” tasks (e.g., simulated or on-road driving performance, simulated aeroplane flying) and/or discrete neuropsychological tests >8 h post (last)-THC (or cannabis) use using an interventional experimental design (any)<sup>15</sup> were eligible for inclusion. The >8-h interval was selected to represent a typical overnight “recovery” period<sup>16</sup> and to minimize overlap with a previous review investigating the shorter-term effects of THC (i.e., ≤12 h).<sup>3</sup> No “upper limit” was imposed. All participant populations (e.g., clinical, “healthy”) and comparator conditions (e.g., placebo, baseline) were accepted. However, studies were excluded if THC was co-administered with another treatment (excluding placebo treatments, other cannabinoids or cannabis constituents, tobacco, or participants’ usual medication) or if results were reported in another included article. Only full-length, English-language, original research articles published in scientific journals were accepted.

Note that if a study contained multiple “intervention arms,” more than one of which was eligible for inclusion, the separate “arms” were treated as discrete “studies,” termed trials, identifiable by the additional letters (e.g., a-d) in the citation.

### Performance outcomes

All objective outcomes measured on safety-sensitive tasks and discrete neuropsychological tests >8 h post-THC administration were accepted. Outcomes measured ≤8 h post-THC administration (on eligible performance tests) were also included. Indeed, these data were used to determine whether the performance tests administered >8 h post-treatment were sensitive to the “acute” (i.e., <8 h post-treatment) effects of THC.

### Quality assessment

Risk of bias (RoB) in included studies was evaluated by two independent assessors (D.M. and A.S.) using (1) the Revised Cochrane Risk of Bias tool (RoB 2.0)<sup>17</sup> and (2) the RoB 2.0 for crossover trials,<sup>18</sup> as appropriate. Both tools examine five potential sources of bias, that is, bias arising from (1) the randomization process; (2) deviations from the intended intervention; (3) missing outcome data; (4) measurement of the outcome; and (5) selective outcome reporting. The latter also examines bias arising from period or carryover effects. Both tools generate an overall “risk rating” (i.e., “low risk,” “some concerns,” “high risk”).

### Data extraction

The extracted data included the following: (1) study design; (2) participant characteristics (e.g., age, sex, body weight, health status, cannabis use behavior); (3) treatment characteristics (e.g., type, composition, route of administration, THC dose); (4) task characteristics (e.g., test, outcomes, number of assessments, length of time between THC administration and the performance test[s]); and (5) standardization procedures employed, that is, the methods used to control participants’ pre-trial and “within-trial” (i.e., up until the >8 h post-treatment assessment) sleep behavior and cannabis, alcohol, caffeine, and other psychoactive drug use. The latter were considered important as they have been shown to influence cognitive and psychomotor performance.<sup>3,19–21</sup>

### Data synthesis

The results of the included studies were synthesized qualitatively, that is, described in terms of whether THC was found to have a statistically significant effect (i.e.,  $p < 0.05$ ) on each performance test (i.e., any one of its outcome measures) relative to the primary comparator, taken as placebo in placebo-controlled trials and baseline (i.e., pre-treatment) elsewhere. If an outcome was analyzed within a complex model (e.g., including three or more treatments and[or] other factors, e.g., time) and no main effect of treatment or relevant interaction(s) was observed, the effect was assumed to be nonsignificant. If a main effect of treatment or relevant interaction was observed, statistical significance was ascertained on the basis of *post-hoc* comparisons.

The results of *post-hoc* comparisons on main effects of treatment that included a time parameter were generalized across all included time points unless the individual time points were compared by treatment

or the comparison incorporated baseline (i.e., pre-treatment) data (in the latter case, the comparison was considered ambiguous). If *post-hoc* comparisons were not performed, or there was any ambiguity in the reported result, the statistical significance of the effect was not presented in this review. Meta-analysis was not performed as studies often failed to report (or graph) the information required to calculate an effect estimate (most studies [80%] were also published >10 years ago [65%, >20 years ago], making it difficult to retrieve the missing data).

Each neuropsychological test was reviewed and categorized into one of the following cognitive domains as previously demonstrated by McCartney et al<sup>3</sup> and shown in Supplementary Table S1: (1) divided attention; (2) executive function; (3) information processing; (4) tracking performance; (5) reaction time; (6) motor function; (7) sustained attention; (8) working memory; (9) perception; (10) learning and(or) memory; and (11) spatial reasoning.

The terms used to describe participants’ cannabis use behavior (e.g., daily, weekly–daily, monthly, etc.) are also as per McCartney et al<sup>3</sup> and defined in Supplementary Table S2. These categories were further collapsed into two main groupings: *regular cannabis users* (which included populations of daily users, weekly users, weekly–daily users) and *other cannabis users* (all other populations) to aid in synthesizing the available literature.

Note that the length of time between THC administration and the beginning of the performance test was calculated from: (1) the last THC exposure if more than one dose was administered before the performance test; and (2) the beginning of the “battery” if multiple tests were administered in succession and their individual start times were not reported.

## Results

### Overview of included studies

Twenty studies ( $n=458$  participants; 79% male, excluding studies that did not report the sex of their participants) were included in this systematic review. These studies administered a total of 345 performance tests (i.e., across all trials and time points >8 h post-treatment). The study selection process is detailed in Supplementary File S1.

The characteristics of the included studies are summarized in Table 1. Briefly, most studies used randomized ( $N=11$ ) or “nonrandomized” (i.e., randomization was not reported;  $N=5$ ) double-blind, placebo-

**Table 1. Characteristics of Included Studies**

	Studies (N) or participants (n)	Citations
Study design		
Randomized, DB, PC	N=11	23,25,26,28,29,31, 34–37,39
Nonrandomized, <sup>a</sup> DB, PC	N=5	22,27,30,32,38
Nonrandomized, SB, <sup>b</sup> PC	N=3	24,33,40
Pre-/post-trial	N=1	41
Participant characteristics		
Male	n=297	—
Female	n=79	—
Sex not specified	n=82 (N=4)	31,32,40,41
Average age ≤ 30 years	N=15	22–24,26,28–31, 34–39,41
Average age > 30 years	N=4	25,31,32,40
Average age not specified	N=2	27,33
"Regular" cannabis users <sup>c</sup>	N=4	22,28,29,37
"Other" cannabis users <sup>c</sup>	N=16	23–27,30–36,38–41
Healthy population	N=20	22–41
Treatment characteristics		
Smoked cannabis or THC	N=13	22–24,28–31,33, 35,37,38,40,41
Ingested cannabis or THC	N=7	25–27,32,34,36,39
THC dose unknown	N=5	22–24,30,35
THC dose (mg) (median [IQR])	16 [11–26] <sup>d</sup>	—
Type of performance test <sup>e</sup>		
Divided attention	N=6	22,25–27,30,33
Executive function	N=4	23,30,34,35
Information processing	N=11	22–28,30,33,34,36
Tracking performance	N=1	33
Reaction time	N=5	22,23,27,34,35
Motor function	N=3	28,30,35
Sustained attention	N=4	27,28,34,37
Working memory	N=6	22,23,30,34–36
Perception	N=3	22,24,30
Learning and(or) memory	N=9	22–25,27,28,30,34,35
Spatial reasoning	N=1	35
Driving performance	N=4	29,37–39
Flying performance	N=3	31,40,41
Unknown	N=2	32,36
Time of performance test		
>8 to 12 h Post-treatment	N=7	22,24–27,33,37
>12 to 24 h Post-treatment	N=16	23,25,28–41
>24 to 48 h Post-treatment	N=8	23,26,28,29,31,34, 35,40
≤8 h Post-treatment	N=18	23–26,28–41
"Recovery" conditions		
Supervised	N=8	22–24,27,30,35, 36,39
Unsupervised	N=10	26,28,29,31–34,38, 40,41
Unclear or not specified	N=2	25,37

<sup>a</sup>Includes studies that did not indicate whether randomization was performed.

<sup>b</sup>Includes studies that did not indicate whether researchers were blinded.

<sup>c</sup>As defined in "Data synthesis" section.

<sup>d</sup>Across all trials where the THC dose is known.

<sup>e</sup>Includes those administered >8 h post-treatment, only.

DB, double blind; IQR, interquartile range; PC, placebo controlled; SB, single blind; THC, Δ<sup>9</sup>-tetrahydrocannabinol.

controlled designs; however, three were single blind and one used a "pre-/post-treatment" design. All included "healthy" participants, only (i.e., no studies of clinical populations were eligible for inclusion). Other (i.e., mostly occasional) cannabis users and populations with an average age ≤ 30 years were studied more often than regular (i.e., weekly, or more often) cannabis users and those with an average age > 30 years, respectively (Table 1). Most studies administered THC by smoking (N=13); the remainder did so through oral ingestion (N=7) (all, but three<sup>22–24</sup> gave a single dose of THC).


The median (interquartile range [IQR]) (last) THC dose was 16 [11–26] mg (where reported; N=15). Two types of "safety-sensitive task" (simulated driving and flying) and a wide range of neuropsychological tests were administered. The number of tests conducted between >8–12, >12–24, and >24–48 h post-treatment was 98, 158, and 89, respectively. Eight studies supervised their participants throughout the >8 h "recovery" period; the remainder (N=12) allowed them to leave the laboratory between assessments. All appeared to assess performance the day following THC administration (i.e., the "next day" or longer). (Note that only the 12-, 10-, and 10-h assessments conducted in Schoedel et al,<sup>25</sup> Ménétrey et al,<sup>26</sup> and Nicholson et al,<sup>27</sup> respectively, are presented in both the current and former<sup>3</sup> review).

### Risk of bias

The results of the RoB assessment are detailed in Supplementary File S2 and summarized in Figure 1. None of the included studies demonstrated an overall "low risk" of bias, although two, Matheson et al<sup>28</sup> and Brands et al,<sup>29</sup> received "low risk" ratings on four out of the five RoB domains assessed. Nine studies were found to have "some concerns," and 11 had a "high risk" of bias. The most common problems were RoB arising from (1) missing outcome data; (2) selective outcome reporting; and (3) carryover effects—with studies often failing to indicate whether any participant discontinued in the trial, analyze their data in accordance with a pre-specified plan, and report the number of participants assigned to each treatment order. Only four studies justified their chosen sample size.

### Standardization procedures

The "standardization procedures" employed, that is, methods used to control participants' pre-trial and



**FIG. 1.** Risk of bias as assessed using the Revised Cochrane Risk of Bias tool (RoB 2.0)<sup>17</sup> and the RoB 2.0 for crossover trials<sup>18</sup> (as appropriate). Green: low risk of bias; orange: some concerns; red: high risk of bias; gray: not applicable (not a crossover trial); N: No; Y: Yes. \*Studies that detected significant detrimental effects of THC on “next day” performance (see Table 2). See Supplementary File S2 for full assessment.

“within-trial” (i.e., up until the >8 h post-treatment assessment) sleep behavior and cannabis, alcohol, caffeine, and other drug use, are summarized in Fig. 2. Studies that supervised their participants throughout the >8-h recovery period ( $N=8$ ) achieved better within-trial standardization than those that did not ( $N=12$ ). However, the latter tended to achieve better pre-trial standardization with most ( $N=9$ ) controlling at least one pre-trial condition. Nicholson et al.<sup>27</sup> and

Chait and Perry<sup>30</sup> implemented the most robust standardization procedures; followed by Matheson et al.<sup>28</sup> and Brands et al.<sup>29</sup> Three studies failed to report implementing any standardization procedure.<sup>25,31,32</sup>

#### “Next Day” effects of THC

The results of the included studies are described below and detailed in Table 2. Note that the studies that administered multiple performance tests can appear

	Pre-Session Standardisation				'Within-Session' Standardisation (Until >8-h Assessment)				
	Cannabis	Alcohol	Other Drugs	Caffeine	Cannabis	Alcohol	Other Drugs	Caffeine	Sleep
<b>Studies in which 'Recovery' was Supervised:</b>									
*Nicholson, et al. <sup>27</sup> (2004)	Withheld (Verified)	Withheld (Verified)	Withheld (Verified)	Withheld (Unverified)	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Controlled (Supervised)
Chait and Perry <sup>20</sup> (1994)	Withheld (Unverified)	Withheld (Verified)	Withheld (Unverified)	Continued	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Controlled (Supervised)
Heishman, et al. <sup>23</sup> (1990)	Withheld (Verified <sup>a</sup> )	Not Specified <sup>b</sup>	Withheld (Unverified)	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Not Specified	Controlled (Supervised)
*Chait <sup>22</sup> (1990)	Withheld (Unverified)	Not Specified	Not Specified	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Controlled (Supervised)
Fant, et al. <sup>35</sup> (1998)	Not Specified <sup>c</sup>	Not Specified <sup>c</sup>	Not Specified <sup>c</sup>	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Not Specified	Controlled (Supervised)
*Chait, et al. <sup>24</sup> (1985)	Not Specified	Not Specified	Not Specified	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Not Specified	Controlled (Supervised)
Rafaelsen, et al. <sup>39</sup> (1973)	Not Specified	Not Specified	Not Specified	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Not Specified	Controlled (Supervised)
Rafaelsen, et al. <sup>36</sup> (1973)	Not Specified	Not Specified	Not Specified	Not Specified	Withheld (Supervised)	Withheld (Supervised)	Withheld (Supervised)	Not Specified	Controlled (Supervised)
<b>Studies in which 'Recovery' was Unsupervised:</b>									
Matheson, et al. <sup>28</sup> (2020)	Withheld (Unverified <sup>d</sup> )	Withheld (Verified)	Withheld (Verified)	Continued	Withheld (Unverified)	Withheld (Verified)	Withheld (Verified)	Continued	Not Specified
Brands, et al. <sup>29</sup> (2019)	Withheld (Unverified <sup>d</sup> )	Withheld (Verified)	Withheld (Verified)	Continued	Withheld (Unverified)	Withheld (Verified)	Withheld (Verified)	Continued	Not Specified
Ménétréy, et al. <sup>26</sup> (2005)	Withheld (Verified)	Withheld (Verified)	Withheld (Verified)	Not Specified	Withheld (Unverified)	Withheld (Unverified)	Withheld (Unverified)	Not Specified	Not Specified
Barnett, et al. <sup>33</sup> (1985)	Withheld (Verified)	Not Specified <sup>b</sup>	Withheld (Verified)	Withheld (Unverified)	Withheld (Unverified)	Not Specified <sup>b</sup>	Withheld <sup>e</sup>	Withheld (Unverified)	Not Specified
Hartley, et al. <sup>37f</sup> (2019)	Withheld (Unverified <sup>d</sup> )	Withheld (Verified)	Withheld (Verified)	Not Specified <sup>g</sup>	Withheld (Unverified)	Not Specified	Not Specified	Not Specified <sup>g</sup>	Not Specified <sup>h</sup>
*Yesavage, et al. <sup>41</sup> (1985)	Withheld (Unverified)	Not Specified <sup>b</sup>	Withheld (Verified)	Not Specified	Withheld (Unverified)	Withheld (Unverified)	Withheld (Unverified)	Not Specified	Not Specified
Curran, et al. <sup>34</sup> (2002)	Withheld (Verified)	Not Specified <sup>i</sup>	Not Specified <sup>i</sup>	Continued	Withheld (Unverified)	Not Specified <sup>i</sup>	Not Specified <sup>i</sup>	Continued	Not Specified
*Leirer, et al. <sup>40</sup> (1991)	Withheld (Verified)	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified
Ronen, et al. <sup>38</sup> (2008)	Withheld (Unverified)	Withheld <sup>k</sup> (Unverified)	Not Specified	Not Specified	Withheld (Unverified)	Withheld <sup>k</sup> (Unverified)	Not Specified	Not Specified	Controlled (Unverified)
Leirer, et al. <sup>31</sup> (1989)	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified
Schoedel, et al. <sup>25f</sup> (2018)	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified
Kielholz, et al. <sup>32</sup> (1973)	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified	Not Specified

**FIG. 2.** Standardization procedures employed in included studies. A substance was considered "withheld" if participants were instructed to avoid using it for  $\geq 24$  h (12 h for caffeine) or if abstinence was "verified." Abstinence was considered "verified" if participants returned a negative "drug test"; that is, a breath test (alcohol), urine screen (other drugs), or blood test (caffeine). Pre-session cannabis abstinence was only "verified" if participants returned a negative blood or urine screen; furthermore, within-session cannabis abstinence was only "verified" if participants were supervised until the  $>8$  h post-treatment assessment. Within-session alcohol and other drug use were also assumed to be "verified" if participants were supervised until this assessment (but could otherwise be demonstrated through a drug test). A substance was considered "continued" if participants were instructed to continue using it as usual. Sleep was considered "controlled" if participants were supervised until the  $>8$  h post-treatment assessment or instructed to obtain sufficient sleep. Adherence to the latter was considered "verified" if an objective measure of sleep quality or duration was obtained. <sup>a</sup>Urine 11-COOH-THC concentrations were  $<20 \text{ ng} \cdot \text{mL}^{-1}$ . <sup>b</sup>Participants were instructed to avoid using "drugs"; however, it is unclear whether this included alcohol. <sup>c</sup>Participants were retained in the laboratory for 2 weeks; however, the pre-session one standardization procedures were not specified. <sup>d</sup>Short-term cannabis abstinence cannot be verified in a population of regular users. <sup>e</sup>It is unclear if this was verified. <sup>f</sup>"Recovery" was assumed to be unsupervised. <sup>g</sup>Individuals with high habitual caffeine intakes were excluded. <sup>h</sup>Individuals with sleep disorders were excluded. <sup>i</sup>Individuals with high habitual alcohol intakes were excluded. <sup>j</sup>Individuals who used psychedelic drugs were excluded. <sup>k</sup>Alcohol intake was restricted to one glass. \*Studies that observed significant negative effects of THC on "next day" performance (see Table 2).

**Table 2. Characteristics and Results of Included Trials (>8-h Treatment, only)**

												Effect of THC (compared to placebo unless otherwise stated)	
Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Time since last THC use	Time since last THC use	Time since last THC use	Time since last THC use	Time since last THC use
Matheson et al <sup>28</sup> _a (2020)	Randomized; DB; PC (BSD)	C: 30 (21M); 22±2 years I: 31 (18 M); 22±2 years	Weekly-daily	Smoked cannabis cigarettes (562±170 mg; 12.5% THC) <td>70.3±21.3<sup>a</sup></td> <td>Grooved pegboard task DSST</td> <td>Time to complete (DH) Number of completed trials</td> <td>24 &amp; 48 h</td> <td>24 &amp; 48 h</td> <td>No significant effect</td> <td><b>THC ↑ number of correct trials at 48 h</b></td> <td></td> <td></td>	70.3±21.3 <sup>a</sup>	Grooved pegboard task DSST	Time to complete (DH) Number of completed trials	24 & 48 h	24 & 48 h	No significant effect	<b>THC ↑ number of correct trials at 48 h</b>		
98	Matheson et al <sup>28</sup> _b (2020)	Randomized; DB; PC (BSD)	C: 30 (21M); 22±2 years I: 30 (26 M); 22±2 years	Weekly-daily	Smoked cannabis cigarettes (752±131 mg; 12.5% THC) <td>94.0±16.4<sup>a</sup></td> <td>Grooved pegboard task DSST</td> <td>Time to complete (non-DH) Number of completed trials</td> <td>24 &amp; 48 h</td> <td>24 &amp; 48 h</td> <td>No significant effect</td> <td><b>THC ↑ number of correct trials at 48 h.</b></td> <td></td>	94.0±16.4 <sup>a</sup>	Grooved pegboard task DSST	Time to complete (non-DH) Number of completed trials	24 & 48 h	24 & 48 h	No significant effect	<b>THC ↑ number of correct trials at 48 h.</b>	
Brands et al <sup>29</sup> _a (2019)	Randomized; DB; PC (BSD)	C: 30 (21M); 22±2 years I: 31 (18 M); 22±2 years	Weekly-daily	Smoked cannabis cigarettes (562±170 mg; 12.5% THC) <td>70.3±21.3<sup>a</sup></td> <td>Simulated driving Speed SDLP Simulated driving (dual task)</td> <td>Simulated driving Speed SDLP</td> <td>24 &amp; 48 h</td> <td>24 &amp; 48 h</td> <td>No significant effect</td> <td></td> <td></td> <td></td>	70.3±21.3 <sup>a</sup>	Simulated driving Speed SDLP Simulated driving (dual task)	Simulated driving Speed SDLP	24 & 48 h	24 & 48 h	No significant effect			

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Brands et al <sup>29</sup> _b (2019)	Randomized; DB; PC (BSD)	C: 30 (21 M); 22 ± 2 years I: 30 (26 M); 22 ± 2 years	Weekly-daily	Smoked cannabis cigarettes (732 ± 131 mg; 12.5% THC) <td>94.0 ± 16.4<sup>a</sup></td> <td>Simulated driving Speed SDLP Speed (dual task)</td> <td>SDLP Speed SDLP Speed</td> <td>24 &amp; 48 h 24 &amp; 48 h</td> <td><b>THC ↓ SDLP at 48 h</b> No significant effect</td>	94.0 ± 16.4 <sup>a</sup>	Simulated driving Speed SDLP Speed (dual task)	SDLP Speed SDLP Speed	24 & 48 h 24 & 48 h	<b>THC ↓ SDLP at 48 h</b> No significant effect
Hartley et al <sup>37</sup> _a (2019)	Randomized; DB; PC (WSD)	15 M; 22 ± 3 years	Weekly	Smoked cannabis cigarettes (9.8% THC; 1 g tobacco) CBN)	10	Simulated driving PVT	SDLP Reciprocal reaction time	12 & 24 h 12 & 24 h	No effect <sup>b</sup> No effect <sup>b</sup>
Hartley et al <sup>37</sup> _b (2019)	Randomized; DB; PC (WSD)	15 M; 22 ± 3 years	Weekly	Smoked cannabis cigarettes (9.8% THC; 1 g tobacco) CBN)	30	Simulated driving PVT	SDLP Reciprocal reaction time	12 & 24 h 12 & 24 h	No effect <sup>b</sup> No effect <sup>b</sup>
Hartley et al <sup>37</sup> _c (2019)	Randomized; DB; PC (WSD)	15 M; 22 ± 3 years	Daily	Smoked cannabis cigarettes (9.8% THC; 1 g tobacco) CBN)	10	Simulated driving PVT	SDLP Reciprocal reaction time	12 & 24 h 12 & 24 h	No effect <sup>b</sup> No effect <sup>b</sup>
Hartley et al <sup>37</sup> _d (2019)	Randomized; DB; PC (WSD)	15 M; 22 ± 3 years	Daily	Smoked cannabis cigarettes (9.8% THC; 1 g tobacco) CBN)	30	Simulated driving PVT	SDLP Reciprocal reaction time	12 & 24 h 12 & 24 h	No effect <sup>b</sup> No effect <sup>b</sup>
Schoedel et al <sup>25</sup> _a (2018)	Randomized; DB; PC (WSD) <sup>c</sup>	43 (31 M) <sup>d</sup> ; 38 ± 9 years	Infrequent-daily	THC capsules	10	Divided attention task HVLTR	Tracking accuracy Delayed recall Percent retained Number of completed trials	12 & 24 h 12 & 24 h	No significant effect No relevant analysis <sup>e</sup>
Schoedel et al <sup>25</sup> _b (2018)	Randomized; DB; PC (WSD) <sup>c</sup>	43 (31 M) <sup>d</sup> ; 38 ± 9 years	Infrequent-daily	THC capsules	30	Divided attention task HVLTR	Tracking accuracy Delayed recall Percent retained Number of completed trials	12 & 24 h 12 & 24 h	No significant effect No relevant analysis <sup>e</sup>
Ronen et al <sup>38</sup> (2008)	DB; PC (WSD)	14 (10 M); 22 ± 2 years	Monthly-weekly	Smoked THC cigarettes	17	Simulated driving RMS lane position RMS speed Reaction time (dual task)	Number of incorrect trials RMS steering deviations Speed	24 h	No significant effect <sup>f</sup>

Table 2. Continued

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Ménétréy et al <sup>26</sup> _a (2005)	Randomized; DB; PC (WSD)	8 M <sup>g</sup> ; range: 22–30 years	Unclear	Hemp milk decoction	16.5	Road sign test Divided attention task	Time to complete Tracking accuracy Number of errors	10 & 25 h 10 & 25 h	Ambiguous <sup>h</sup>
Ménétréy et al <sup>26</sup> _b (2005)	Randomized; DB; PC (WSD)	8 M <sup>g</sup> ; range: 22–30 years	Unclear	Hemp milk decoction	45.7	Road sign test Divided attention task	Time to complete Tracking accuracy Number of errors	10 & 25 h 10 & 25 h	Ambiguous <sup>h</sup>
Ménétréy et al <sup>26</sup> _c (2005)	Randomized; DB; PC (WSD)	8 M <sup>g</sup> ; range: 22–30 years	Unclear	THC capsules	20	Road sign test Divided attention task	Time to complete Tracking accuracy Number of errors	10 & 25 h 10 & 25 h	Ambiguous <sup>h</sup>
Nicholson et al <sup>27</sup> _a (2004)	DB; PC (WSD)	8 (4 M); range 21–34 years	Current nonusers	Oromucosal spray	15	Word memory recall	Reaction time Immediate recall Delayed recall	10 h	<b>THC ↓ immediate and delayed recall at 10 h</b>
						Digit memory recall 6-Letter memory recall	Reaction time Number of errors	10 h	No significant effect
						DSST	Reaction time Number of errors	10 h	No significant effect
						Multi-attribute task	Number of completed trials System monitoring RT System monitoring RA Communications RT	10 h	No significant effect
							Resource management RT Resource management RA		
							Tracking accuracy Reciprocal reaction time	10 h	
							Number of errors		No significant effect
							Reaction time		No significant effect
							Number of errors		No significant effect
							Immediate recall		No significant effect
							Delayed recall		<b>THC ↑ reaction time at 10 h</b>
							Reaction time	10 h	No significant effect
							Number of errors	10 h	No significant effect
							Number of completed trials	10 h	No significant effect
							System Monitoring RT System Monitoring RA Communications RT	10 h	
							Resource management RA		
							Tracking accuracy		

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Nicholson et al <sup>27</sup> _c (2004)	DB; PC (WSD)	8 (4 M); range 21–34 years	Current nonusers	Oromucosal spray (15 mg CBD)	15	Choice reaction time task Sustained attention task Word memory recall Digit memory recall 6-Letter memory recall DSST	Reciprocal reaction time Number of errors Reaction time Number of errors Immediate recall Delayed recall Reaction time Number of errors Reaction time Number of errors Number of completed trials	10 h	No significant effect No significant effect No significant effects No significant effects No significant effects No significant effect No significant effect No significant effect No significant effect No significant effect
Curran et al <sup>34</sup> _a (2002)	Randomized; DB; PC (WSD)	15 M; 24±2 years	Unclear	THC capsules	7.5	Multi-attribute task System monitoring RT System monitoring RA Communications RT Resource management RA Resource management RT	Tracking accuracy Reciprocal reaction time Number of errors Reaction time Number of errors Immediate recall Delayed recall Proportion of hits	10 h	No significant effect No significant effect Ambiguous

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Curran et al <sup>34</sup> _b (2002)	Randomized; DB; PC (WSD)	15 M; 24±2 years	Unclear	THC capsules	15	Buschke selective reminding task RVIPT	Immediate recall Delayed recall Proportion of hits Reaction time	24 & 48 h	Ambiguous
Fant et al <sup>35</sup> _a (1998)	Randomized; DB; PC (WSD)	10 M; 27 years, range: 24–31 years	Monthly–weekly	Smoked cannabis (1.8% THC)	"Eight Puffs" (dose unknown)	Baddley reasoning task Subtract serial sevens task Choice reaction time task Digit cancellation task	Reaction time Number of errors Reaction time Number of errors Reaction time Number of errors Time to complete (ST) Number of errors (ST) Time to complete (DT) Number of errors (DT) Reaction time	24 & 48 h 24 & 48 h	No significant effect No significant effect

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Fant et al <sup>35</sup> <sup>b</sup> (1998)	Randomized; DB; PC (WSD)	10 M; 27 years, range: 24–31 years	Monthly–weekly Smoked cannabis cigarettes (3.6% THC)	"Eight Puffs" (dose unknown)	Smooth-pursuit eye movements	Central speed (fixed) Peripheral speed (fixed) Peripheral speed (varied)	23, 24 & 25 h	Ambiguous <sup>1</sup>	
Chait and Perry <sup>30</sup> (1994)	DB; PC (WSD)	14 (10 M); 25 years, range: 21–34 years	Monthly–daily Smoked cannabis cigarettes (3.6% THC)	"Eight Puffs" (dose unknown)	Time production task	Reaction time Time interval (30 sec) Time interval (60 sec)	11 & 18 h	No significant effect	
Leirer et al <sup>40</sup> (1991)	"Blinded" <sup>a</sup> ; PC (WSD)	9 (Sex NS); 31 years, range: 24–40 years	Unclear	Smoked cannabis cigarettes	20	Number of trials attempted Number of correct trials Percent correct Digit span	11 & 18 h	No significant effect	
						Backward digit span task Logical reasoning task Visual divided attention task	11 & 18 h	No significant effect	
						Hit rate Reaction time Secondary target errors Number of false alarms Immediate recall	11 & 18 h	No significant effect	
						Free recall task Simulated flying	24 & 48 h	<b>THC ↓ performance at 24 h</b>	

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Chait <sup>22</sup> (1990)	DB; PC (WSD)	12 (9 M); 21 years, range: 18–26 years	Weekly—daily	Smoked cannabis cigarettes (800–900 mg; 2.1% THC)	"Eight Puffs" <sup>a,k</sup> (dose unknown)	Time production task	Time interval	12, 12 & 12h <sup>k</sup>	<b>THC ↓ time interval (all days)<sup>j,m</sup></b>
					Simple reaction time task	NS		12, 12 & 12h <sup>k</sup>	No significant effect
					Forward digit span task	Digit span		12, 12 & 12h <sup>k</sup>	No significant effect
					Visual divided attention task	Reaction time	Reaction time	12, 12 & 12h <sup>k</sup>	<b>THC ↑ reaction time (all days)<sup>j</sup></b>
					Number of misses	Number of misses			
					Number of false alarms	Reaction time variability			
					NS	NS		12, 12 & 12h <sup>k</sup>	No significant effect
					Choice reaction time task	Digit span		12, 12 & 12h <sup>k</sup>	<b>THC ↓ digit span on day 1</b>
					Backward digit span task	DSST		12, 12 & 12h <sup>k</sup>	No significant effect
					Buschke selective Reminding task	NS		12, 12 & 12h <sup>k</sup>	No significant effect
					Two letter search task	Number of trials attempted	Number of trials attempted	23, 25, 27, 29	Results not adequately reported
					Logical reasoning task	Percent correct	Number of correct trials attempted	23, 25, 27, 29	Results not adequately reported
					Digit recall task	Number of correct trials attempted	Number of correct trials	23, 25, 27, 29	Results not adequately reported
					Serial addition and subtraction task	Percent correct	Number of trials attempted	23, 25, 27, 29	Results not adequately reported
					Circular lights task	Percent correct	Number of correct responses	23, 25, 27, 29	Results not adequately reported

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Heishman et al <sup>23_b</sup> (1990)	Randomized; DB; PC (WSD)	3 M; range 27–29 years	Unclear	Smoked cannabis (2.57% THC)	"2× Cigarette" (dose unknown) <sup>b</sup>	Two letter search task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Logical reasoning task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Digit recall task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Serial addition and subtraction task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Circular lights task	Number of correct responses	19, 21, 23, 25 & 27 h	Results not adequately reported
Heishman et al <sup>23_c</sup> (1990)	Randomized; DB; PC (WSD)	2 M; range 27–29 years	Unclear	Smoked cannabis (2.57% THC)	"4× Cigarette" (dose unknown) <sup>c</sup>	Two letter search task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Logical reasoning task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Digit recall task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Serial addition and subtraction task	Number of trials attempted Number of correct trials Percent correct	19, 21, 23, 25 & 27 h	Results not adequately reported
					Number of trials attempted Number of correct trials Percent correct	Circular lights task	Number of correct responses	19, 21, 23, 25 & 27 h	Results not adequately reported
Leirer et al <sup>31_a</sup> (1989)	Randomized; DB; PC (WSD)	9 (Sex NS); 26 years, range: 18–29 years	Unclear	Smoked cannabis cigarettes	10	Simulated flying	Performance score (calm)	24 & 48 h	No significant effect
Leirer et al <sup>31_b</sup> (1989)	Randomized; DB; PC (WSD)	9 (Sex NS); 26 years, range: 18–29 years	Unclear	Smoked cannabis cigarettes	20	Simulated flying	Performance score (calm)	24 & 48 h	No significant effect

(continued)

**Table 2.** Continued

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Leirer et al <sup>31_c</sup> (1989)	Randomized; DB; PC (WSD)	9 (Sex NS); 38 years, range: 30–48 years	Unclear	Smoked cannabis cigarettes	10	Simulated flying	Performance score (calm)	24 & 48 h	No significant effect
Leirer et al <sup>31_d</sup> (1989)	Randomized; DB; PC (WSD)	9 (Sex NS); 38 years, range: 30–48 years	Unclear	Smoked cannabis cigarettes	20	Simulated flying	Performance score (turbulent)	24 & 48 h	No significant effect
Barnett et al <sup>33_a</sup> (1985)	"Blinded" <sup>a,i</sup> ; PC (WSD)	8 M; range: 22–33 years	Unclear	Smoked cannabis cigarettes (700 mg; 1% THC)	100 µg kg <sup>-1</sup> (6.8–7.3 mg)	Visual search task	Reaction time	10, 12 & 23 h	No effect <sup>b</sup>
Barnett et al <sup>33_b</sup> (1985)	"Blinded" <sup>a,i</sup> ; PC (WSD)	8 M; range: 22–33 years	Unclear	Smoked cannabis cigarettes (700 mg; 1% THC)	200 µg kg <sup>-1</sup> (14–15 mg)	Divided attention task	Reaction time	10, 12 & 23 h	No effect <sup>b</sup>
Barnett et al <sup>33_c</sup> (1985)	"Blinded" <sup>a,i</sup> ; PC (WSD)	8 M; range: 22–33 years	Unclear	Smoked cannabis cigarettes (700 mg; 1% THC)	250 µg kg <sup>-1</sup> (17–18 mg)	Critical tracking task	Tracking accuracy	10, 12 & 23 h	No effect <sup>b</sup>
Chait et al <sup>24_a</sup> (1985)	"Blinded" <sup>a,i</sup> ; PC (WSD)	13 M; 25 years, range: 21–35 years	Infrequent-daily	Smoked cannabis cigarettes (1 g; 2.9% THC)	"Ten Puffs" (dose unknown)	Visual search task	Reaction time	10, 12 & 23 h	No effect <sup>b</sup>
Chait et al <sup>24_b</sup> (1985)	"Blinded" <sup>a,i</sup> ; PC (WSD)	6 M; age NS	Unclear	Smoked cannabis cigarettes (1 g; 2.9% THC)	"Five Puffs" (dose unknown)	Divided attention task	Tracking accuracy	10, 12 & 23 h	No effect <sup>b</sup>
						DSST	Number of correct trials	9.5 h	No significant effect
						Time production task	Time interval ('10 sec) Time interval (30 sec)	9.5 h	No significant effect
							Time to complete (suit)	9.5 h	No significant effect
							Immediate recall	9.5 h	No significant effect
								9.5 h	THC ↑ time interval (10 & 30 sec) at 9.5 h compared to target
									Results not reported
									Results not reported
									Results not reported
									Results not reported
									Results not reported

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Yesavage et al <sup>41</sup> (1985)	Pre-/post-trial	10 (Sex NS); 29 years	Unclear	Smoked cannabis cigarettes	19	Simulated flying	Distance off-center on landing Lateral deviation Vertical deviation Aileron (number of changes) Aileron (mean size) Elevations (number of changes) Elevations (mean size) Number of throttle changes	24 h	THC ↑ distance off-center on landing, lateral deviation, aileron (number of changes), aileron (mean size) and elevations (mean size) at 24 h compared to baseline
Rafaelsen et al <sup>39_a</sup> (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	8	Simulated driving	Brake time Start time Number of gear changes	~15 h	No significant effect <sup>b</sup>
Rafaelsen et al <sup>39_b</sup> (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	12	Simulated driving	Mean speed Brake time Start time Number of gear changes	~15 h	No significant effect <sup>b</sup>
Rafaelsen et al <sup>39_c</sup> (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	12	Simulated driving	Mean speed Brake time Start time Number of gear changes	~15 h	No significant effect <sup>b</sup>
Rafaelsen et al <sup>39_d</sup> (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	16	Simulated driving	Mean speed Brake time Start time Number of gear changes	~15 h	No significant effect <sup>b</sup>
Rafaelsen et al <sup>36_a</sup> (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	8	Digit span task (direction NS) Addition test	Digit span Time to complete Number of errors	~15 h	No significant effect <sup>b</sup>
						Subtract serial sevens task Finger labyrinths task Bourdon's cancellation test	Time to complete Number of errors Number of letters scanned Number of errors	~15 h	No significant effect <sup>b</sup>
								~15 h	No significant effect <sup>b</sup>

(continued)

**Table 2. Continued**

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Rafaelson et al <sup>36</sup> _b (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	12	Digit span task (direction NS) Addition test	Digit span	~15 h	No significant effect <sup>p</sup>
				Subtract serial sevens task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Finger labyrinths task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Bourdon's cancellation test		Number of letters scanned Number of errors		~15 h	No significant effect <sup>p</sup>
Rafaelson et al <sup>36</sup> _c (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	12	Digit span task (direction NS) Addition test	Digit span	~15 h	No significant effect <sup>p</sup>
				Subtract serial sevens task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Finger labyrinths task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Bourdon's cancellation test		Number of letters scanned Number of errors		~15 h	No significant effect <sup>p</sup>
Rafaelson et al <sup>36</sup> _d (1973)	Randomized; DB; PC (WSD)	8 M; range: 21–29 years	Unclear	Oral cannabis (baked into cake)	16	Digit span task (direction NS) Addition test	Digit span	~15 h	No significant effect <sup>p</sup>
				Subtract serial sevens task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Finger labyrinths task		Time to complete Number of errors		~15 h	No significant effect <sup>p</sup>
				Bourdon's cancellation test		Number of letters scanned Number of errors		~15 h	No significant effect <sup>p</sup>
Kiehholz et al <sup>32</sup> _a (1973)	DB; PC (BSD)	54 <sup>q</sup> (Sex NS); 34 years	Unclear	THC capsules	350 $\mu\text{g} \cdot \text{kg}^{-1}$ (~24.5 mg) <sup>r</sup>	Tapping task	Taps (comfortable) (right) Taps (comfortable) (left) Taps (fast) (right) Taps (fast) (left)	17.5 h	Results not adequately reported
				Spiral rotor task		NS			Results not adequately reported
				The compensation apparatus		NS		17.5 h	Results not adequately reported
				The tracking apparatus		Reaction time Frequency of pedal pressure		17.5 h	Results not adequately reported

(continued)

Table 2. Continued

Citation	Study design	Participants	Usual cannabis use behavior	Treatment	THC dose (mg)	Performance test	Outcomes	Time since last THC use	Effect of THC (compared to placebo unless otherwise stated)
Kiehholz et al <sup>32</sup> _b (1973)	DB; PC (BSD)	54 <sup>q</sup> (Sex NS); 34 years	Unclear	THC capsules	400 µg·kg <sup>-1</sup> (~28 mg) <sup>r</sup>	Tapping task	Taps (comfortable) (R) Taps (comfortable) (L) Taps (fast) (R) Taps (fast) (L) NS	17.5 h	Results not adequately reported
Kiehholz et al <sup>32</sup> _c (1973)	DB; PC (BSD)	54 <sup>q</sup> (Sex NS); 34 years	Unclear	THC capsules	450 µg·kg <sup>-1</sup> (~31.5 mg) <sup>r</sup>	Tapping task	The compensation apparatus The tracking apparatus Reaction time Frequency of pedal pressure Taps (comfortable) (right) Taps (comfortable) (left) Taps (fast) (right) Taps (fast) (left) NS	17.5 h	Results not adequately reported
						Spiral rotor task	NS	17.5 h	Results not adequately reported

All "Effects of THC" are in comparison to placebo unless otherwise stated; comparisons to baseline are only reported when those to placebo were not conducted or not reported. Significant effects are in **bold** text.

<sup>a</sup>Cigarettes were smoked *ad libitum*.

<sup>b</sup>The authors modeled the "behavioral pharmacokinetics" of THC rather than investigating its effect at specific times post-treatment; however, their modeling still suggests impairment resolves within 8 h.

<sup>c</sup>Although "double blinded," participants had to demonstrate a capacity to distinguish between THC and placebo (in a "Quantification Phase") to be eligible for inclusion.

<sup>d</sup>Only 35 of these participants were included in the analyses investigating THC's effects on cognitive function.

<sup>e</sup>Only the "minimum" and "maximum" performance scores were presented and subjected to statistical analysis.

<sup>f</sup>Compared to "20 minutes post-placebo" (as performance was not assessed 24 h post-placebo).

<sup>g</sup>It is unclear whether six or eight participants completed the cognitive function tests.

<sup>h</sup>It is unclear how the time parameter was handled in these statistical analyses (see also "Next Day" effects of THC section).

<sup>i</sup>The authors indicate that THC decreased pursuit speeds at 1.75 h, but do not clearly describe its effects at the other time points.

<sup>j</sup>The authors do not state whether a single- or double-blind design was used.

<sup>k</sup>Participants completed a total of five smoking periods involving "eight puffs" each: (1) 9 PM Friday; (2) 3 PM Saturday; (3) 9 PM Saturday; (4) 3 PM Sunday, and (5) 9 PM Sunday; cognitive function was assessed 12 h after each evening (9 PM) smoking period.

<sup>l</sup>Main effect of treatment across all 3 days.

<sup>m</sup>This effect is described as "negative" in this article (since any change in time production could indicate "impairment"); however, it is worth noting that participants were closer to the target time on THC than placebo.

<sup>n</sup>The first cigarette was administered 4 h before the second.

<sup>o</sup>The first two cigarettes were administered 4 h before the second two.

<sup>p</sup>We presume these comparisons are against placebo.

<sup>q</sup>Total number across all four treatment groups.

<sup>r</sup>Value estimated at a body weight of 70 kg.

BSD, between-subject design; C, control group; CBD, cannabidiol; CBN, cannabinol; CPT, continuous performance test; DB, double blind; DH, dominant hand; DSST, digit symbol substitution test; DT, double target; HVL-T-R, Hopkins Verbal Learning Test Revised; I, intervention group; L, left; M, male participants; NS, not specified; PC, placebo controlled; PVT, psychomotor vigilance task; R, right; R, correlation coefficient; RA, response accuracy; RT, reaction time; RVIPt, rapid visual information processing task; SB, single blind; SDLP, standard deviation of lane position; ST, single target; WSD, within subject design.

in multiple “subsections” (e.g., if they observed negative “next day” effects on some tests, but not others).

**No “Next Day” effects.** A total of 180 neuropsychological tests and 29 safety-sensitive tasks showed no “next day” effect of THC ( $N=18$  divided attention<sup>25,27,30,33</sup>;  $N=12$  executive function<sup>30,34,35</sup>;  $N=32$  information processing<sup>22,24,27,28,30,33,34,36</sup>;  $N=6$  tracking performance<sup>33</sup>;  $N=23$  reaction time<sup>22,27,34,35</sup>;  $N=6$  motor function<sup>28,30</sup>;  $N=19$  sustained attention<sup>27,28,34,37</sup>;  $N=22$  working memory<sup>22,30,34–36</sup>;  $N=2$  perception<sup>30</sup>;  $N=26$  learning and(or) memory<sup>22,24,27,28,30,35</sup>;  $N=6$  spatial reasoning<sup>35</sup>;  $N=8$  unknown<sup>36</sup>;  $N=20$  simulated driving<sup>29,37–39</sup>; and  $N=9$  simulated flying<sup>31,40</sup>). Seventy, 82, and 28 of these 180 neuropsychological tests and 4, 17, and 8 of these 29 safety-sensitive tasks were conducted between  $>8$ –12,  $>12$ –24, and  $>24$ –48 h post-treatment, respectively.

No “next day” effect was observed across a total of 16 published studies.<sup>22,24,25,27–31,33–40</sup> Most of these 16 studies ( $N=9$ ) used randomized double-blind, placebo-controlled designs<sup>25,28,29,31,34–37,39</sup> ( $N=4$  non-randomized double blind<sup>22,27,30,38</sup> and  $N=3$  non-randomized single blind<sup>24,33,40</sup>), involved other cannabis users ( $N=12$ ),<sup>24,25,27,30,31,33–36,38–40</sup> and administered THC by smoking ( $N=11$ ).<sup>22,24,28–31,33,35,37,38,40</sup> The median [IQR] THC dose was 15 [10–20] mg (where reported;  $N=12$ ).<sup>25,27–29,31,33,34,36–40</sup>

With respect to RoB, half of these 16 studies were rated as having “some concerns” ( $N=8$ ),<sup>22,24,25,28–30,37,40</sup> and the other half had a “high risk” of bias ( $N=8$ ).<sup>27,31,33–36,38,39</sup> Of those with “some concerns,” two received “low risk” ratings on four of the five RoB domains assessed<sup>28,29</sup> and three employed “robust” standardization procedures.<sup>28–30</sup>

**Negative “Next Day” effects.** A total of 10 neuropsychological tests conducted between  $>8$  and 12 h post-treatment and two safety-sensitive tasks conducted 24 h post-treatment indicated negative (i.e., impairing) “next day” effects of THC ( $N=2$  learning and[or] memory<sup>27</sup>;  $N=4$  perception<sup>22,24</sup>;  $N=1$  working memory<sup>22</sup>;  $N=3$  divided attention<sup>22</sup>; and  $N=2$  simulated flying<sup>40,41</sup>).

These negative “next day” effects were observed across a total of five published studies.<sup>22,24,27,40,41</sup> None of these studies used randomized double-blind, placebo-controlled designs ( $N=2$  nonrandomized double-blind<sup>22,27</sup>;  $N=2$  nonrandomized single-blind<sup>24,40</sup>; and  $N=1$  pre-/post-treatment design<sup>41</sup>).

Most involved other cannabis users ( $N=4$ )<sup>24,27,40,41</sup> and administered THC by smoking ( $N=4$ ).<sup>22,24,40,41</sup> THC doses were 5, 15, 19, and 20 mg (where reported;  $N=3$ ).<sup>27,40,41</sup>

With respect to RoB, three of these five studies were rated as having “some concerns,”<sup>22,24,40</sup> and two had a “high risk” of bias.<sup>27,41</sup> Of those with “some concerns,” none employed “robust” standardization procedures.

**Positive “Next Day” effects.** Two neuropsychological tests and one safety-sensitive task, all administered 48 h post-treatment, indicated positive (i.e., enhancing) “next day” effects of THC ( $N=2$  information processing<sup>28</sup> and  $N=1$  simulated driving<sup>29</sup>).

These positive “next day” effects were observed across two published studies<sup>28,29</sup> conducted in the same investigation: a randomized double-blind, placebo-controlled trial. Participants were regular cannabis users and smoked either  $70.3 \pm 21.3$  or  $94.0 \pm 16.4$  mg THC *ad libitum*.

With respect to RoB, both studies were rated as having “some concerns”—but received “low risk” ratings on four of the five domains assessed.<sup>28,29</sup> Both also employed “robust” standardization procedures.

**Unclear “Next Day” effects.** A total of 121 performance tests indicated “unclear” or ambiguous “next day” effects of THC (i.e., insufficient information was provided to accurately determine the result) (Table 2). These unclear “next day” effects were observed across a total of seven published studies,<sup>23–26,32,34,35</sup> three of which reported all of their relevant results ( $N=99$  performance tests) in a manner that was of limited use to the current review. First, Ménétry et al<sup>26</sup> reported using a Kruskal-Wallis test to compare cognitive function data across four different treatments. This is problematic as these data were collected at seven different time points (plus baseline) and the authors do not explain how the time parameter was handled in their analyses.

Second, Heishman et al<sup>23</sup> were unable to perform statistical analyses as only three participants completed their trial (and only two completed treatment arm “c”). Third, the results of Kielholz et al<sup>32</sup> were poorly described and could not be reliably interpreted. These studies and tests were retained for completeness, but will not be discussed further.

#### “Acute Effects” of THC

It is important to consider whether the 345 performance tests administered  $>8$  h post-treatment also


demonstrated “acute” (i.e., <8 h post-treatment) effects of THC. Indeed, a lack of impairment at, say, 24 h is a more definitive illustration of no “next day” effects on a performance test if impairment had been evident on that same test at shorter durations following THC (i.e., <8 h post-treatment). The relevant results are detailed in Supplementary File S1 and summarized in Figure 3. We note the following: only 20% ( $N=42$ ) of the tests that showed no “next day” effects of THC also demonstrated “acute” effects (i.e., initial impairment). Most did not (42%;  $N=88$ ). The remainder either did not assess (17%;  $N=36$ ) or adequately describe (21%;  $N=43$ ) the acute effects of THC.

## Discussion

This systematic review found little by way of high-quality scientific evidence to support the assertion

that cannabis use impairs “next day” performance. Indeed, of the 345 performance tests reviewed, only 12 indicated negative (i.e., impairing) “next day” effects of THC. Notably, the five studies that observed these effects were all published >18 years ago (four, >30 years ago) and found to have significant methodological limitations.

Only two investigations: the flight simulator studies of Leirer et al<sup>40</sup> and Yesavage et al<sup>41</sup> provided any evidence of THC-induced impairment persisting beyond 12 h. Both studies administered ~20 mg THC to a poorly characterized participant population (i.e., their cannabis use behavior and sex were not reported) by smoking (cannabis) and reported impairment 24 h post-treatment. However, they also employed suboptimal designs (i.e., “pre-/post-treatment” and non-randomized, single blind, placebo controlled) and



a: Matheson et al. (2020)\_a, b; Brands et al. (2019)\_a, b; Schoedel et al. (2018)\_a; Curran et al. (2002)\_a, b; Fant et al. (1998)\_a, b; Chait & Perry (1994); Leirer et al. (1989)\_a, c; Chait et al. (1985)\_a; Rafaelsen et al. (1973a)\_a, b; Rafaelsen et al. (1973b)\_a, b, c, d.  
b: Matheson et al. (2020)\_a, b; Brands et al. (2019)\_b.

c: Matheson et al. (2020)\_b; Schoedel et al. (2018)\_b; Ronen et al. (2008); Curran et al. (2002)\_a, b; Chait & Perry (1994); Leirer et al. (1991); Leirer et al. (1989)\_b, d; Chait et al. (1985)\_a; Rafaelsen et al. (1973a)\_c, d; Rafaelsen et al. (1973b)\_b, c, d.

d: Leirer et al. (1991); Yesavage et al. (1985); Chait et al. (1985)\_a

e: Fant et al. (1998)\_a, b

f: Nicholson et al. (2004)\_a, b, c; Chait (1990)

g: Nicholson et al. (2004)\_a, b; Chait (1990)

h: Hartley et al. (2019)\_a, b, c, d; Barnett et al. (1985)\_a, b, c.

i: Schoedel et al. (2018)\_a, b; Ménétrey et al. (2005)\_a, b, c; Curran et al. (2002)\_a, b; Heishman et al. (1990)\_a, b, c; Chait et al. (1985)\_b; Kielholz et al. (1973)\_a, b, c.

**FIG. 3.** A total of 345 performance tests were administered >8 h post-treatment. This figure shows the number demonstrating “no effect,” a “positive effect,” a “negative effect,” and an “unclear effect” of THC (i.e., on any one of its outcome measures) >8–12, >12–24, and >24–48 h post-treatment. Counts are further subcategorized based on whether the performance test also demonstrated “no effect,” a “negative effect,” or an “unclear effect” “acutely” (i.e., anytime ≤8 h post-treatment) (or if acute effects were not assessed). Unused subgroupings were omitted from this figure. Note: reductions in driving speed ≤8 h post-treatment were not considered either “positive” or “negative” and were therefore omitted from this analysis. See Table 2 and Supplementary Table S3 for full results. THC, Δ<sup>9</sup>-tetrahydrocannabinol.

inadequate standardization procedures (Fig. 2), one indicating a “high risk” of bias (due to missing outcome data and the randomization process employed).<sup>41</sup> It can further be assumed that flight simulator technology was very rudimentary at this stage in history (i.e., ~1990) and noted that these “next day” effects were not replicated in a third flight simulator study (employing a superior randomized, double-blind, placebo-controlled design) conducted by the same group of authors.<sup>31</sup>

Three additional investigations Nicholson et al,<sup>27</sup> Chait et al,<sup>24</sup> and Chait<sup>22</sup> reported impaired cognitive performance between >8 and 12 h after THC use. Again, however, each of these studies employed suboptimal designs (Table 2) and had either a “high risk” of bias (due to missing outcome data)<sup>27</sup> or inadequate standardization procedures<sup>22,24</sup> (Fig. 2); two also involved an unknown dose of THC.<sup>22,24</sup> Of further note is the fact that many of the effects observed across these three studies ( $N=4$  out of 10)—and the only effect observed in Chait et al<sup>24</sup>—were on “time production” tests (i.e., during which participants estimate when a given amount of time has elapsed, e.g., 120 sec). These tests may be of limited relevance to driving and workplace safety. In addition, time estimations were often closer to the target on THC than placebo (i.e., arguably enhanced).<sup>22</sup>

The remaining “negative” effects could be due, in part, to certain methodological factors. For example, the oromucosal THC (5 and 15 mg) preparation used in Nicholson et al<sup>27</sup> would be expected to elicit longer lasting impairment than inhaled THC.<sup>3,42</sup> Chait<sup>22</sup> also utilized an unusually demanding treatment protocol in which participants completed five separate “smoking sessions” over a 48-h period. Overall, however, these “next day” effects did not appear to be associated with a specific methodological factor (e.g., dose, route of administration or whether regular or occasional users were assessed) and should be interpreted with caution.

The “next day” effects of alcohol use have also received some scientific attention. Indeed, a recent meta-analysis showed that “alcohol hangover” had a small to moderate detrimental effect on cognitive performance (e.g., sustained attention, psychomotor speed, short-/long-term memory).<sup>43</sup> The “next day” effects of THC use could not be quantified in this review as studies often failed to report the information required to calculate an effect estimate. However, the small number of significant effects observed

would suggest that a THC “hangover” is unlikely to be more impairing than an alcohol hangover, which is generally tolerated among drivers and individuals employed in safety-sensitive positions.

A total of 209 performance tests conducted across 16 published studies showed no “next day” effects of THC.<sup>22,24,25,27–31,33–40</sup> Most of these 16 studies used randomized double-blind, placebo-controlled designs ( $N=9$ ),<sup>25,28,29,31,34–37,39</sup> but still had methodological limitations. Indeed, half had a “high risk” of bias (often due to missing outcome data)<sup>27,31,33–36,38,39</sup> and most used inadequate standardization procedures<sup>22,24,25,27,31,33–40</sup> (Fig. 2). In addition, only three justified their chosen sample sizes (Fig. 1) (and none used noninferiority analysis to test the specific hypothesis that THC *does not* impair “next day” performance<sup>44</sup>).

One additional concern is that 42% of the tests showing no “next day” effects of THC also failed to demonstrate “acute” (i.e., <8 h post-treatment) THC-induced impairment (Fig. 3). This is important as “next day” effects seem unlikely to occur in the absence of initial impairment, which could reflect the use of lower THC doses and/or tests or cognitive domains that are relatively insensitive to the effects of THC. The collective results of these 16 studies should therefore be interpreted with some degree of caution.

Nevertheless, two recent studies, both finding no “next day” effects of THC, were identified as having employed good-quality research methods: Matheson et al<sup>28</sup> and Brands et al.<sup>29</sup> These studies were conducted within the same investigation: a randomized double-blind, placebo-controlled trial in which participants (weekly-daily cannabis users) smoked either  $70.3 \pm 21.3$  or  $94.0 \pm 16.4$  mg THC (cannabis) *ad libitum*. Both studies had “some” RoB—but received “low risk” ratings on four of the five domains assessed (Fig. 1).

They also justified their chosen sample size ( $n=91$ ) (Fig. 1) and employed relatively robust standardization procedures (Fig. 2). Motor function, learning and(or) memory, information processing, sustained attention, and simulated driving performance were not impaired 24 or 48 h post-treatment in these investigations. Some positive (i.e., enhancing) effects were unexpectedly observed 48 h post-treatment. In addition, only learning and(or) memory demonstrated “acute” (i.e., <8 h post-treatment) impairment. However, these findings provide some confirmation that high doses of inhaled THC are unlikely to impair “next day” performance in regular cannabis users.

Further high-quality studies investigating the “next day” effects of THC in both occasional and medicinal cannabis uses are, of course, required, as are studies involving the administration of oral THC. Until the results of such studies become available, there remains some justification for a cautious regulatory approach. However, policy makers should bear in mind that the implementation of very conservative workplace regulations can have serious consequences (e.g., termination of employment with a positive drug test) and impact the quality of life of individuals who are required to abstain from medicinal cannabis use to treat conditions such as insomnia or chronic pain for fear of a positive workplace or roadside drug test.

The following factors might also be considered in future studies of this nature. First, while most of the studies conducted to date have administered a single dose of THC, many individuals (in particular, regular cannabis users) do not consume THC in this manner under real-world conditions. High-quality studies involving daily users of medical and nonmedical cannabis would therefore be valuable. Second, performance on safety-sensitive tasks (e.g., driving, flying) and neuropsychological tests may be susceptible to “practice” (learning) and “fatigue” (loss of motivation) effects over time, and these might be better controlled in future studies. Indeed, in addition to masking “acute” effects of THC, practice effects might be attenuated under the influence of THC such that “next day” effects appear to be present.

## Conclusion

A small number of lower-quality studies have observed negative (i.e., impairing) ‘next day’ effects of THC on cognitive function and safety-sensitive tasks. However, higher-quality studies, and a large majority of performance tests, have not. Overall, it appears that there is limited scientific evidence to support the assertion that cannabis use impairs ‘next day’ performance. However, further research, in particular, studies involving both occasional and medicinal cannabis users and oral THC administration, is strongly recommended.

## Authors' Contributions

All authors (D.M., A.S., and I.S.M.) contributed to the conception and design of the research project; D.M. and A.S. completed data acquisition; and all authors contributed to the interpretation of the research data, were involved in drafting and critically revising the article, and approved the final submitted version.

## Author Disclosure Statement

ISM is a consultant to Kinoxis Therapeutics and Psylo Ltd and has received a speakers honorarium from Janssen and consultancy fees from the Medical Cannabis Industry Association. He holds a number of patents for cannabinoid and non-cannabinoid therapeutics. ISM also acts as an expert witness in legal cases where issues of cannabis-induced impairment may be relevant. AS has received consulting fees from the Medical Cannabis Industry Association and GlaxoSmithKline Consumer Healthcare Australia Pty Ltd trading as Haleon. DM has received consulting fees from the Medical Cannabis Industry Association.

## Funding Information

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. D.M., A.S.S., and I.S.M. receive salary support from the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded center for medicinal cannabis research at the University of Sydney.

## Supplementary Material

- Supplementary File S1
- Supplementary File S2
- Supplementary Table S1
- Supplementary Table S2
- Supplementary Table S3

## References

1. United Nations: Office on Drugs and Crime. World Drug Report 2021. Vienna, Austria, 2021.
2. Lintzeris N, Mills L, Suraev A, et al. Medical cannabis use in the Australian community following introduction of legal access: The 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). *Harm Reduct J* 2020;17(1):37.
3. McCartney D, Arkell T, Irwin C, et al. Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. *Neurosci Biobehav Rev* 2021;126:175–193.
4. Rogeberg O, Elvik R. Response to Li, et al. (2017): Cannabis use and crash risk in drivers. *Addiction* 2017;112(7):1316.
5. Rogeberg O. A meta-analysis of the crash risk of cannabis-positive drivers in culpability studies—avoiding interpretational bias. *Accid Anal Prev* 2019;123:69–78.
6. Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. *Addiction* 2016;111(8):1348–1359.
7. Arkell T, McCartney D, McGregor I. Medical cannabis and driving. *Aust J Gen Pract* 2021;50(6):357–362.
8. Spindle T, Cone E, Schlienz N, et al. Acute pharmacokinetic profile of smoked and vaporized cannabis in human blood and oral fluid. *J Anal Toxicol* 2019;43(4):233–258.
9. Vandrey R, Herrmann E, Mitchell J, et al. Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. *J Anal Toxicol* 2017;41(2):83–99.
10. Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: A systematic review of human evidence. *Neurosci Biobehav Rev* 2018;93:1–25.

11. Occupational and Environmental Medical Association of Canada. Position Statement on the Implications of Cannabis Use for Safety-Sensitive Work. 2018. Available from: <https://oemac.org/wp-content/uploads/2018/09/Position-Statement-on-the-Implications-of-cannabis-use.pdf> [last accessed: November 14, 2022].
12. Beckson M, Hagtvedt R, Els C. Cannabis use before safety-sensitive work: What delay is prudent? *Neurosci Biobehav Rev* 2022;133:104488.
13. Higgins J, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane; 2021.
14. Pope Jr H, Gruber A, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: The current status of research. *Drug Alcohol Depend* 1995;38(1):25–34.
15. Aggarwal R, Ranganathan P. Study designs: Part 4. Interventional studies. *Perspect Clin Res* 2019;10(3):137–139.
16. Kronholm E, Härmä M, Hublin C, et al. Self-reported sleep duration in Finnish general population. *J Sleep Res* 2006;15(3):276–290.
17. Higgins J, Savović J, Page M, et al. Chapter 8: Assessing Risk of Bias in a Randomized Trial. In: Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). (Higgins J, Thomas J, Chandler J, et al. eds.) Cochrane; 2021.
18. Higgins J, Eldridge S, Li T. Chapter 23: Including Variants on Randomized Trials. In: Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). (Higgins J, Thomas J, Chandler J, et al. eds.) Cochrane; 2021.
19. Goel N, Rao H, Durmer J, et al. Neurocognitive consequences of sleep deprivation. *Semin Neurol* 2009;29(4):320–339.
20. Moskowitz H, Florentino D. A Review of the Literature on the Effects of Low Doses of Alcohol on Driving-Related Skills 2000 (DOT-HS-809-028; NTIS-PB2000105778). Department of Transportation: Washington, DC, USA; 2000.
21. Irwin C, Khalesi S, Desbrow B, et al. Effects of acute caffeine consumption following sleep loss on cognitive, physical, occupational and driving performance: A systematic review and meta-analysis. *Neurosci Biobehav Rev* 2020;108:877–888.
22. Chait LD. Subjective and behavioral effects of marijuana the morning after smoking. *Psychopharmacology* 1990;100(3):328–333.
23. Heishman S, Huestis M, Henningfield J, et al. Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. *Pharmacol Biochem Behav* 1990;37(3):561–565.
24. Chait L, Fischman M, Schuster C. "Hangover" effects the morning after marijuana smoking. *Drug Alcohol Depend* 1985;15(3):229–238.
25. Schoedel K, Szeto I, Setnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. *Epilepsy Behav* 2018;88:162–171.
26. Ménétry A, Augsburger M, Favrat B, et al. Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Δ9-THC. *J Anal Toxicol* 2005;29(5):327–338.
27. Nicholson A, Turner C, Stone B, et al. Effect of Δ-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. *J Clin Psychopharmacol* 2004;24(3):305–313.
28. Matheson J, Mann R, Sproule B, et al. Acute and residual mood and cognitive performance of young adults following smoked cannabis. *Pharmacol Biochem Behav* 2020;194:172937.
29. Brands B, Mann R, Wickens C, et al. Acute and residual effects of smoked cannabis: Impact on driving speed and lateral control, heart rate, and self-reported drug effects. *Drug Alcohol Depend* 2019;205:107641.
30. Chait L, Perry J. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. *Psychopharmacology* 1994;115(3):340–349.
31. Leirer VO, Yesavage J, Morrow D. Marijuana, aging, and task difficulty effects on pilot performance. *Aviat Space Environ Med* 1989;60(12):1145–1152.
32. Kielholz P, Hobi V, Ladewig D, et al. An experimental investigation about the effect of cannabis on car driving behaviour. *Pharmacopsychiatry* 1973;6(01):91–103.
33. Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics of marijuana. *Psychopharmacology* 1985;85(1):51–56.
34. Curran V, Brignell C, Fletcher S, et al. Cognitive and subjective dose-response effects of acute oral Δ 9-tetrahydrocannabinol (THC) in infrequent cannabis users. *Psychopharmacology* 2002;164(1):61–70.
35. Fant R, Heishman S, Bunker E, et al. Acute and residual effects of marijuana in humans. *Pharmacol Biochem Behav* 1998;60(4):777–784.
36. Rafaelson L, Christrup H, Bech P, et al. Effects of cannabis and alcohol on psychological tests. *Nature* 1973;242(5393):117–118.
37. Hartley S, Simon N, Larabi A, et al. Effect of smoked cannabis on vigilance and accident risk using simulated driving in occasional and chronic users and the pharmacokinetic-pharmacodynamic relationship. *Clin Chem* 2019;65(5):684–693.
38. Ronen A, Gershon P, Drobner H, et al. Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. *Accid Anal Prev* 2008;40(3):926–934.
39. Rafaelson O, Bech P, Christiansen J, et al. Cannabis and alcohol: Effects on simulated car driving. *Science* 1973;179(4076):920–923.
40. Leirer VO, Yesavage J, Morrow D. Marijuana carry-over effects on aircraft pilot performance. *Aviat Space Environ Med* 1991;62(3):221–227.
41. Yesavage J, Leirer O, Denari M, et al. Carry-over effects of marijuana intoxication on aircraft pilot performance: A preliminary report. *Am J Psychiatry* 1985;142(11):1325–1329.
42. Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. *Clin Chem* 2011;57(1):66–75.
43. Gunn C, Mackus M, Griffin C, et al. A systematic review of the next-day effects of heavy alcohol consumption on cognitive performance. *Addiction* 2018;113(12):2182–2193.
44. McCartney D, Suraev A, Doohan P, et al. Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. *J Psychopharmacol* [Epub ahead of print]; DOI: 10.1177/02698811221095356.

**Cite this article as:** McCartney D, Suraev A, McGregor IS (2023) The "Next Day" effects of cannabis use: a systematic review, *Cannabis and Cannabinoid Research* 8:1, 92–114, DOI: 10.1089/can.2022.0185.

#### Abbreviations Used

IQR = interquartile range

RoB = risk of bias

THC = Δ<sup>9</sup>-tetrahydrocannabinol